Could liquid, room-temperature vaccines solve the cold-chain challenge?

Imperial College London spinout AlphaVectors Biotech is developing nanoparticles that could keep vaccines stable in liquid form at room temperature, potentially reducing reliance on costly cold-chain infrastructure